Inogen Launches Rove 4 Portable Oxygen Concentrator, Delivering the Highest Oxygen Output in the Lightest Weight 4-Setting POC
Inogen, Inc. (Nasdaq: INGN) has launched the Inogen® Rove 4™ Portable Oxygen Concentrator in the U.S. market. This innovative device offers:
- The highest oxygen output in the lightest weight 4-setting POC
- Up to 840ml/min of medical grade oxygen
- Weighs less than 3 lbs with standard battery
- Three battery configurations providing up to 5 hours and 45 minutes of operation
- Patented pulse-dose Intelligent Delivery Technology®
- Best-in-class expected service life of up to 8 years
The Rove 4 aims to empower patients with choices that may help them with normal activities of daily living. Kevin Smith, President and CEO, expressed excitement about the launch and its potential positive impact on patients requiring oxygen therapy.
Inogen, Inc. (Nasdaq: INGN) ha lanciato il Inogen® Rove 4™ Concentratore Portatile di Ossigeno sul mercato statunitense. Questo dispositivo innovativo offre:
- La massima erogazione di ossigeno nel concentratore POC a 4 impostazioni più leggero
- Fino a 840ml/min di ossigeno di grado medicale
- Pesa meno di 3 libbre con batteria standard
- Tre configurazioni della batteria che forniscono fino a 5 ore e 45 minuti di funzionamento
- Tecnologia di Erogazione Intelligente a Pulsos® brevettata
- Durata di servizio prevista best-in-class fino a 8 anni
Il Rove 4 mira a permettere ai pazienti di avere scelte che possano aiutarli nelle normali attività quotidiane. Kevin Smith, Presidente e CEO, ha espresso entusiasmo per il lancio e il suo potenziale impatto positivo sui pazienti che necessitano di terapia con ossigeno.
Inogen, Inc. (Nasdaq: INGN) ha lanzado el Inogen® Rove 4™ Concentrador Portátil de Oxígeno en el mercado de EE. UU. Este dispositivo innovador ofrece:
- La mayor producción de oxígeno en el concentrador POC más liviano de 4 configuraciones
- Hasta 840ml/min de oxígeno de grado médico
- Pesa menos de 3 libras con batería estándar
- Tres configuraciones de batería que proporcionan hasta 5 horas y 45 minutos de funcionamiento
- Tecnología de Entrega Inteligente por Pulso® patentada
- Vida útil esperada de clase mundial de hasta 8 años
El Rove 4 tiene como objetivo empoderar a los pacientes con opciones que pueden ayudarles con las actividades diarias normales. Kevin Smith, Presidente y CEO, expresó su entusiasmo por el lanzamiento y su potencial impacto positivo en los pacientes que requieren terapia con oxígeno.
Inogen, Inc. (Nasdaq: INGN)가 미국 시장에 Inogen® Rove 4™ 포터블 산소 농축기를 출시했습니다. 이 혁신적인 장치는 다음과 같은 기능을 제공합니다:
- 가장 가벼운 4단계 POC에서 최대 산소 출력
- 최대 840ml/min의 의료용 산소
- 표준 배터리로 3파운드 미만의 무게
- 최대 5시간 45분의 사용 시간을 제공하는 세 가지 배터리 구성
- 특허받은 펄스 용량 지능형 전달 기술®
- 최대 8년의 기대 서비스 수명
Rove 4는 환자들이 일상적인 활동을 수행하는 데 도움이 되는 선택지를 제공하는 것을 목표로 합니다. Kevin Smith, 사장 및 CEO는 이 출시와 산소 치료가 필요한 환자들에게 미칠 긍정적인 영향에 대해 기대감을 표명했습니다.
Inogen, Inc. (Nasdaq: INGN) a lancé le Concentrateur Portable d'Oxygène Inogen® Rove 4™ sur le marché américain. Cet appareil innovant offre :
- La plus haute production d'oxygène dans le concentrateur POC le plus léger à 4 réglages
- Jusqu'à 840ml/min d'oxygène de qualité médicale
- Pèse moins de 3 livres avec la batterie standard
- Trois configurations de batterie permettant jusqu'à 5 heures et 45 minutes de fonctionnement
- Technologie d'Intelligent Delivery à Pulses® brevetée
- Durée de vie de classe mondiale attendue jusqu'à 8 ans
Le Rove 4 vise à donner aux patients des choix qui peuvent les aider dans leurs activités quotidiennes normales. Kevin Smith, Président et CEO, a exprimé son enthousiasme pour le lancement et son impact positif potentiel sur les patients nécessitant une thérapie à l'oxygène.
Inogen, Inc. (Nasdaq: INGN) hat den Inogen® Rove 4™ Tragbaren Sauerstoffkonzentrator auf dem US-Markt eingeführt. Dieses innovative Gerät bietet:
- Die höchste Sauerstoffabgabe im leichtesten 4-Bereich POC
- Bis zu 840ml/min medizinischen Sauerstoff
- Wiegt weniger als 3 Pfund mit Standardbatterie
- Drei Batteriekonfigurationen, die bis zu 5 Stunden und 45 Minuten Betrieb ermöglichen
- Patentierte Pulsdosis Intelligente Liefertechnologie®
- Erwartete Lebensdauer der Spitzenklasse von bis zu 8 Jahren
Der Rove 4 soll Patienten die Wahlmöglichkeiten geben, die ihnen helfen können, alltägliche Aktivitäten normal auszuführen. Kevin Smith, Präsident und CEO, äußerte seine Begeisterung über den Start und dessen potenziell positiven Einfluss auf Patienten, die eine Sauerstofftherapie benötigen.
- Launch of Inogen® Rove 4™ Portable Oxygen Concentrator with highest oxygen output in lightest 4-setting POC
- Device weighs less than 3 lbs with standard battery, enhancing portability
- Up to 5 hours and 45 minutes of operation with three battery configurations
- Utilizes patented pulse-dose Intelligent Delivery Technology® for efficient oxygen delivery
- Best-in-class expected service life of up to 8 years, indicating durability and potential long-term value
- None.
Insights
The launch of Inogen's Rove 4 Portable Oxygen Concentrator represents a significant advancement in oxygen therapy technology. With its highest oxygen output in the lightest weight 4-setting POC, it addresses a critical need for patients requiring supplemental oxygen while maintaining mobility.
Key features that stand out:
- Fourth flow setting delivering up to 840ml/min of medical-grade oxygen
- Lightweight design under 3 lbs
- Battery life up to 5 hours and 45 minutes
- Patented Intelligent Delivery Technology® for efficient oxygen delivery
- Expected service life of up to 8 years
This innovation could potentially improve quality of life for oxygen-dependent patients by enhancing their ability to perform daily activities. The endorsement from Dr. Neil MacIntyre of Duke University Medical Center adds credibility to the product's potential impact on patient care.
The launch of Rove 4 positions Inogen (INGN) favorably in the competitive portable oxygen concentrator market. With a market cap of
- Potential for increased market share in the home respiratory care segment
- Opportunity to capture a larger portion of the growing elderly population requiring oxygen therapy
- Possible boost in recurring revenue from consumables and service
However, investors should consider:
- Initial costs associated with product launch and marketing
- Potential impact on profit margins during the early adoption phase
- Competition's response and the pace of market acceptance
Overall, this launch aligns with Inogen's strategy to innovate in the portable oxygen concentrator space and could drive long-term value for shareholders.
With an additional, fourth flow setting delivering up to 840ml/min of medical grade oxygen, in a lightweight user-friendly design of less than 3 lbs1 and three battery configurations providing up to 5 hours and 45 minutes of operation2, the versatility of Rove 4 empowers patients with choices that may help them with normal activities of daily living.
“We are pleased to announce the launch of Rove 4, a meaningful step forward in our intent to serve patients in need of oxygen therapy while allowing them to remain ambulatory,” said Kevin Smith, President and Chief Executive Officer. “This is an important milestone, and we are excited to work with patients and prescribers to deliver the positive impact of Rove 4 technology.”
According to Neil MacIntyre, MD, of Duke University Medical Center, “It is exciting to see the continuing innovation of portable oxygen concentrators to help advance the ambulation of long-term oxygen therapy patients. The Inogen Rove 4 should play a meaningful role on this journey.”
The Rove 4 utilizes Inogen’s patented pulse-dose Intelligent Delivery Technology®3. This technology provides unparalleled triggering sensitivity to quickly detect a breath and deliver oxygen within the first 250 milliseconds of the inspiration, where oxygen has the most effect on lung gas exchange.
Designed for reliability, the Rove 4 offers a best-in-class expected service life of up to 8 years4.
1 2.9 lbs when used with standard battery.
2 At setting 1.
3 Pulse-dose based Intelligent Delivery Technology® ensures that oxygen therapy is delivered efficiently and effectively in all modes of use.
4 When used for less than 8 hours per day.
About Inogen
Inogen, Inc. (Nasdaq: INGN) is a leading global medical technology company offering innovative respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing innovative best-in-class portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its oxygen therapy products widely available allowing patients the chance to remain ambulatory while managing the impact of their disease.
For more information, please visit www.inogen.com.
Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements with respect to the announced changes to management; statements concerning or implying Inogen’s future financial performance; the ability of management personnel to contribute to the execution of Inogen’s strategic plans and goals. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “possible,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks related to its announced management and organizational changes, and risks arising from the possibility that Inogen will not realize anticipated future financial performance or strategic goals. In addition, Inogen's business is subject to numerous additional risks and uncertainties, including, among others, risks relating to market acceptance of its products; competition; its sales, marketing and distribution capabilities; its planned sales, marketing, and research and development activities; interruptions or delays in the supply of components or materials for, or manufacturing of, its products; seasonal variations; unanticipated increases in costs or expenses; risks associated with international operations; and the possibility that Inogen will not realize anticipated revenue from recent or future technology acquisitions or that expenses and costs related thereto will exceed Inogen’s expectations. Information on these and additional risks, uncertainties, and other information affecting Inogen’s business operating results are contained in its Annual Report on Form 10-K for the period ended December 31, 2023, its Quarterly Report on Form 10-Q for the calendar quarter ended June 30, 2024 and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looking statements except as may be required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241008928593/en/
Source: Inogen, Inc.
FAQ
What are the key features of Inogen's new Rove 4 Portable Oxygen Concentrator (INGN)?
How long can the Inogen Rove 4 (INGN) operate on a single charge?
What is the expected service life of the Inogen Rove 4 Portable Oxygen Concentrator (INGN)?
What technology does the Inogen Rove 4 (INGN) use for oxygen delivery?
